2-(isopropylsulfonyl)benzylamine hydrochloride salt | 918810-43-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(isopropylsulfonyl)benzylamine hydrochloride salt
• 英文别名: 2-(isopropylsulfonyl)benzylamine hydrochloride；1-{2-[(1-methylethyl)sulfonyl]phenyl}methanamine hydrochloride；(2-propan-2-ylsulfonylphenyl)methanamine;hydrochloride
• CAS: 918810-43-2
• 化学式: C₁₀H₁₅NO₂S*ClH
• 分子量: 249.762
• InChiKey: ZIWGJHZUVPXFSR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.75
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  68.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(isopropylsulfonyl)benzylamine hydrochloride salt 、 2-cyano-2-(3,4-dichloro-5-oxo-2,5-dihydrofuran-2-yl)acetamide 在 potassium carbonate 、 盐酸 作用下， 以 乙醇 、 甲醇 、 乙酸乙酯 为溶剂， 反应 16.0h， 生成 5-chloro-2-imino-1-{2-[(1-methylethyl)sulfonyl]benzyl}-1,2-dihydropyridine-3-carboxamide hydrochloride
  参考文献：
  名称：

  Iminopyridine Derivatives and Use Thereof

  摘要：

  本发明旨在提供一种具有α1D肾上腺素受体拮抗作用的咪唑啉衍生物化合物，该化合物可用作预防或治疗下尿路疾病等疾病的药剂。本发明提供了一种由下式表示的化合物或其盐：其中每个符号如规范中定义。

  公开号：

  US20090270393A1
• 作为产物：
  描述：

  2-(Isopropylsulfonyl)benzonitrile 在 palladium 10% on activated carbon 盐酸 、 氢气 作用下， 以 甲醇 为溶剂， 反应 2.0h， 以98%的产率得到2-(isopropylsulfonyl)benzylamine hydrochloride salt
  参考文献：
  名称：

  Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants

  摘要：

  本发明提供了式(I)或(IV)的新型苯基甘氨酰衍生物：或其立体异构体、互变异构体、药学上可接受的盐、溶剂合物或前药，其中变量W、W1、Y、Z、R7、R8、R9和R11如本文所定义。这些化合物是选择性因子VIIa的抑制剂，可用作药物。

  公开号：

  US20070003539A1

文献信息

• Iminopyridine derivatives and use thereof
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US07982044B2

  公开（公告）日：2011-07-19

  The present invention aims to provide an iminopyridine derivative compound having an α1D adrenergic receptor antagonistic action, which is useful as an agent for the prophylaxis or treatment of a lower urinary tract disease and the like. The present invention provides a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

  本发明旨在提供一种具有α1D肾上腺素受体拮抗作用的咪唑吡啶衍生物化合物，其可用作预防或治疗下尿路疾病等药物。本发明提供了一种由式所表示的化合物，其中每个符号如规范中所定义，或其盐。
• Iminopyridine derivatives and uses thereof
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US07985863B2

  公开（公告）日：2011-07-26

  The present invention aims to provide an iminopyridine derivative compound having an α1D adrenergic receptor antagonistic action, which is useful as an agent for the prophylaxis or treatment of a lower urinary tract disease and the like. The present invention provides a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

  本发明旨在提供一种具有α1D肾上腺素受体拮抗作用的亚胺吡啶衍生物化合物，该化合物可用作预防或治疗下尿路疾病等药物。本发明提供的化合物由下式表示：其中每个符号如规范中所定义，或其盐。
• IMINOPYRIDINE DERIVATIVES AND USE THEREOF
  申请人：YOSHIDA Masato

  公开号：US20110124874A1

  公开（公告）日：2011-05-26

  The present invention aims to provide an iminopyridine derivative compound having an α 1D adrenergic receptor antagonistic action, which is useful as an agent for the prophylaxis or treatment of a lower urinary tract disease and the like. The present invention provides a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

  本发明旨在提供一种具有α1D肾上腺素能受体拮抗作用的吲哚啉衍生物化合物，其可用作预防或治疗下尿路疾病等药物。本发明提供一种由以下式表示的化合物，其中每个符号如规范中所定义，或其盐。
• IMINOPYRIDINE DERIVATIVES AND USES THEREOF
  申请人：YOSHIDA Masato

  公开号：US20110124875A1

  公开（公告）日：2011-05-26

  The present invention aims to provide an iminopyridine derivative compound having an α 1D adrenergic receptor antagonistic action, which is useful as an agent for the prophylaxis or treatment of a lower urinary tract disease and the like. The present invention provides a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

  本发明旨在提供一种具有α1D肾上腺素能受体拮抗作用的咪唑吡啶衍生物化合物，其作为预防或治疗下尿路疾病等药物是有用的。本发明提供了一种由下式表示的化合物，其中每个符号如规范中所定义，或其盐。
• Design and Synthesis of Phenylpyrrolidine Phenylglycinamides As Highly Potent and Selective TF-FVIIa Inhibitors
  作者：Xiaojun Zhang、Wen Jiang、Swanee Jacutin-Porte、Peter W. Glunz、Yan Zou、Xuhong Cheng、Alexandra H. Nirschl、Nicholas R. Wurtz、Joseph M. Luettgen、Alan R. Rendina、Gang Luo、Timothy M. Harper、Anzhi Wei、Rushith Anumula、Daniel L. Cheney、Robert M. Knabb、Pancras C. Wong、Ruth R. Wexler、E. Scott Priestley

  DOI：10.1021/ml400453z

  日期：2014.2.13

  Inhibitors of the Tissue Factor/Factor VIIa (TF-FVIIa) complex are promising novel anticoagulants that show excellent efficacy and minimal bleeding in preclinical models. On the basis of a zwitterionic phenylglycine acylsulfonamide 1, a phenylglycine benzylamide 2 was shown to possess improved permeability and oral bioavailability. Optimization of the benzylamide, guided by X-ray crystallography, led to a potent TF-FVIIa inhibitor 18i with promising oral bioavailability, but promiscuous activity in an in vitro safety panel of receptors and enzymes. Introducing an acid on the pyrrolidine ring, guided by molecular modeling, resulted in highly potent, selective, and efficacious TF-FVIIa inhibitors with clean in vitro safety profile. The pyrrolidine acid 20 showed a moderate clearance, low volume of distribution, and a short t(1/2) in dog PK studies.